Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of AZD1775 in Combination With Belinostat in Relapsed and Refractory Myeloid Malignancies and Selected Untreated Patients With Acute Myeloid Leukemia

NCT02381548 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT02381548
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02381548 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of AZD1775 in Combination With Belinostat in Relapsed and Refractory Myeloid Malignancies and Selected Untreated Patients With Acute Myeloid Leukemia
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Terminated
Start date
August 18, 2015
Completion date
May 23, 2018
Enrollment
20 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, acute myeloid leukemia post cytotoxic therapy, blast phase chronic myeloid leukemia, bcr-abl1 positive, myelodysplastic syndrome, recurrent adult acute myeloid leukemia, recurrent chronic myeloid leukemia, bcr-abl1 positive, refractory acute myeloid leukemia, refractory chronic myeloid leukemia, bcr-abl1 positive, secondary acute myeloid leukemia